### Abstract

We have shown (hat the absolute peripheral blood (PB) CD34 count generated using the IMAGN 2000® microvolume fluorimeter(MVF; 50nl sample size, 45 min tunaround) and the STELLer® CD34 assay correlates with the CD34+ cell dose/kg through rat the apheresis procedure. Thus, use of a PB CD34 algorithm can determine the optirial collection day and/or duration. Several groups have established standardized flow cytometry methods for CD34 enumeration. Both methods were used to assess the algorithm-genera ed final PBSC products of 42 hématologie malignancy patients [indolent lymphoma (FND):n = 19, sensitive non-Hodgkin's lymphoma and Hodgkin's disease (SEN):n =12, multi )le myeloma (MM):n= 11]. All were enrolled on a critical pathway for PBSC mobilizat on which included priming with cyclophosphamide (CY, 2.5 g/m2) and G-CSF (10 meg/kg). The algorithm-set collection time uses 4-5×10^{6} CD34+ cells/kg as the optimal target yit d. Patients (n=38) with sufficient collection kinetics were harvested within 1 apheresis procedure. The mean (95% CI) CD34 percentage for all grafts was 1.2% (0.7) for MVF and 1.8 %(1.1 ) for flow (Sutherland method) with the final product containing 8.8x 106(E .0) and 14.1×10^{6}(9.7) CD34+ cells/kg (p0.04, t test), respectively. Review of the 3 diseise cohorts showed differences in collection kinetics, but there were no(by t t;st analysis)significant differences found between methods of CD34 enumeration. Since CC 34 dose and platelet engraftment are strongly correlated, a 4th cohort (n=8; patients requir ng 15 days to achieve a platelet count 50,000/ul) was also analyzed. Although not significant (p=0.09), the harvest would be considered low optimal by MVF but quite adequate by flow. In conclusion, MVF is a valuable point of care methodology for graft assessm ;nt given its fast turn around time and minimal technical skill level. The availability of commercial CD34 controls will allow closer correlation of the 2 methods, especi: lly within an institution. Cohort Microvolume Fluorimetry Flow Cytometry Gran 500 Plat 50lt %CD34 CD34/kg (xlO6) % CD34 CD34/kg (×10^{6}) Day: Day: MM 1.6 11.2 2.2 17.5 9 12 SEN 0.8 5.6 1.3 10.7 10 13 ND 1.9 10.9 3.3 19.6 11 13 Plat d 15 0.4 4.1 0.7 7.3 11 18 All values represent the mean determination for each cohort.

Original language | English (US) |
---|---|

Journal | Blood |

Volume | 96 |

Issue number | 11 PART I |

State | Published - 2000 |

### Fingerprint

### ASJC Scopus subject areas

- Hematology

### Cite this

*Blood*,

*96*(11 PART I).

**Assessment of CD34 apheresis yields by microvolume fluorimetry (MVF) or conventional flow cytometry : Is there an effect on clinical outcome?** / Noga, S. J.; Myers, B.; Miller, S. C.; Loper, K. A.; Meusel, S.; Flinn, I.; Vogelsang, Georgia Boyce; O'Donnell, P. V.

Research output: Contribution to journal › Article

*Blood*, vol. 96, no. 11 PART I.

}

TY - JOUR

T1 - Assessment of CD34 apheresis yields by microvolume fluorimetry (MVF) or conventional flow cytometry

T2 - Is there an effect on clinical outcome?

AU - Noga, S. J.

AU - Myers, B.

AU - Miller, S. C.

AU - Loper, K. A.

AU - Meusel, S.

AU - Flinn, I.

AU - Vogelsang, Georgia Boyce

AU - O'Donnell, P. V.

PY - 2000

Y1 - 2000

N2 - We have shown (hat the absolute peripheral blood (PB) CD34 count generated using the IMAGN 2000® microvolume fluorimeter(MVF; 50nl sample size, 45 min tunaround) and the STELLer® CD34 assay correlates with the CD34+ cell dose/kg through rat the apheresis procedure. Thus, use of a PB CD34 algorithm can determine the optirial collection day and/or duration. Several groups have established standardized flow cytometry methods for CD34 enumeration. Both methods were used to assess the algorithm-genera ed final PBSC products of 42 hématologie malignancy patients [indolent lymphoma (FND):n = 19, sensitive non-Hodgkin's lymphoma and Hodgkin's disease (SEN):n =12, multi )le myeloma (MM):n= 11]. All were enrolled on a critical pathway for PBSC mobilizat on which included priming with cyclophosphamide (CY, 2.5 g/m2) and G-CSF (10 meg/kg). The algorithm-set collection time uses 4-5×106 CD34+ cells/kg as the optimal target yit d. Patients (n=38) with sufficient collection kinetics were harvested within 1 apheresis procedure. The mean (95% CI) CD34 percentage for all grafts was 1.2% (0.7) for MVF and 1.8 %(1.1 ) for flow (Sutherland method) with the final product containing 8.8x 106(E .0) and 14.1×106(9.7) CD34+ cells/kg (p0.04, t test), respectively. Review of the 3 diseise cohorts showed differences in collection kinetics, but there were no(by t t;st analysis)significant differences found between methods of CD34 enumeration. Since CC 34 dose and platelet engraftment are strongly correlated, a 4th cohort (n=8; patients requir ng 15 days to achieve a platelet count 50,000/ul) was also analyzed. Although not significant (p=0.09), the harvest would be considered low optimal by MVF but quite adequate by flow. In conclusion, MVF is a valuable point of care methodology for graft assessm ;nt given its fast turn around time and minimal technical skill level. The availability of commercial CD34 controls will allow closer correlation of the 2 methods, especi: lly within an institution. Cohort Microvolume Fluorimetry Flow Cytometry Gran 500 Plat 50lt %CD34 CD34/kg (xlO6) % CD34 CD34/kg (×106) Day: Day: MM 1.6 11.2 2.2 17.5 9 12 SEN 0.8 5.6 1.3 10.7 10 13 ND 1.9 10.9 3.3 19.6 11 13 Plat d 15 0.4 4.1 0.7 7.3 11 18 All values represent the mean determination for each cohort.

AB - We have shown (hat the absolute peripheral blood (PB) CD34 count generated using the IMAGN 2000® microvolume fluorimeter(MVF; 50nl sample size, 45 min tunaround) and the STELLer® CD34 assay correlates with the CD34+ cell dose/kg through rat the apheresis procedure. Thus, use of a PB CD34 algorithm can determine the optirial collection day and/or duration. Several groups have established standardized flow cytometry methods for CD34 enumeration. Both methods were used to assess the algorithm-genera ed final PBSC products of 42 hématologie malignancy patients [indolent lymphoma (FND):n = 19, sensitive non-Hodgkin's lymphoma and Hodgkin's disease (SEN):n =12, multi )le myeloma (MM):n= 11]. All were enrolled on a critical pathway for PBSC mobilizat on which included priming with cyclophosphamide (CY, 2.5 g/m2) and G-CSF (10 meg/kg). The algorithm-set collection time uses 4-5×106 CD34+ cells/kg as the optimal target yit d. Patients (n=38) with sufficient collection kinetics were harvested within 1 apheresis procedure. The mean (95% CI) CD34 percentage for all grafts was 1.2% (0.7) for MVF and 1.8 %(1.1 ) for flow (Sutherland method) with the final product containing 8.8x 106(E .0) and 14.1×106(9.7) CD34+ cells/kg (p0.04, t test), respectively. Review of the 3 diseise cohorts showed differences in collection kinetics, but there were no(by t t;st analysis)significant differences found between methods of CD34 enumeration. Since CC 34 dose and platelet engraftment are strongly correlated, a 4th cohort (n=8; patients requir ng 15 days to achieve a platelet count 50,000/ul) was also analyzed. Although not significant (p=0.09), the harvest would be considered low optimal by MVF but quite adequate by flow. In conclusion, MVF is a valuable point of care methodology for graft assessm ;nt given its fast turn around time and minimal technical skill level. The availability of commercial CD34 controls will allow closer correlation of the 2 methods, especi: lly within an institution. Cohort Microvolume Fluorimetry Flow Cytometry Gran 500 Plat 50lt %CD34 CD34/kg (xlO6) % CD34 CD34/kg (×106) Day: Day: MM 1.6 11.2 2.2 17.5 9 12 SEN 0.8 5.6 1.3 10.7 10 13 ND 1.9 10.9 3.3 19.6 11 13 Plat d 15 0.4 4.1 0.7 7.3 11 18 All values represent the mean determination for each cohort.

UR - http://www.scopus.com/inward/record.url?scp=33748660244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748660244&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748660244

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART I

ER -